Haddock R C, Spell M L, Baker C D, Grammer J R, Parks J M, Speidel M, Booyse F M
Department of Medicine, University of Alabama, Birmingham 35294.
J Biol Chem. 1991 Nov 15;266(32):21466-73.
Recombinant human single-chain urokinase (rscu-PA), two-chain urokinase (tcu-PA), and diisopropyl-fluorophosphate-treated tcu-PA (DFP-tcu-PA) bound to cultured human and porcine endothelial cells in a rapid, saturable, dose-dependent and reversible manner. Analysis of specific binding results in cultured human umbilical vein endothelial cells (HUVECs) gave the following estimated values for Kd and Bmax: 0.57 +/- 0.08 nM (mean +/- S.E.) and 188,000 +/- 18,000 sites/cell for 125I-labeled rscu-PA; 0.54 +/- 0.10 nM and 132,000 +/- 23,900 sites/cells for 125I-labeled tcu-PA; 0.89 +/- 0.14 nM and 143,000 +/- 30,300 sites/cell for 125I-labeled DFP-tcu-PA, respectively. Values for Kd were similar for primary and subcultured (six passages) HUVECs, but Bmax values were lower in subcultured HUVECs. Similar Kd values were found in cultured porcine endothelial cells; however, Bmax values varied depending on the endothelial cell type. All 125I-labeled urokinase forms yielded similar cross-linked approximately 110-kDa ligand-receptor complexes with cultured HUVECs, and 125I-labeled DFP-tcu-PA bound to a single major approximately 55-kDa protein in whole-cell lysates (ligand blotting/autoradiography), suggesting the presence of a single major approximately 55-kDa urokinase receptor in cultured HUVECs. The approximately 55-kDa urokinase receptor, isolated from several separate batches of cultured HUVECs (3-5 micrograms of protein, approximately 1 x 10(9) cells), by ligand affinity chromatography, exhibited the following properties: retained biologic activity as evidenced by its ability to bind 125I-labeled rscu-PA by ligand blotting/autoradiography and formation of a cross-linked 125I-labeled approximately 110-kDa rscu-PA-receptor complex; single-chain approximately 55-kDa protein, following reduction; complete conversion to and formation of a single major deglycosylated approximately 35-kDa protein, following treatment with N-glycanase.
重组人单链尿激酶(rscu-PA)、双链尿激酶(tcu-PA)和经二异丙基氟磷酸处理的tcu-PA(DFP-tcu-PA)以快速、可饱和、剂量依赖性和可逆的方式与培养的人及猪内皮细胞结合。对培养的人脐静脉内皮细胞(HUVECs)特异性结合结果的分析得出了以下Kd和Bmax的估计值:125I标记的rscu-PA为0.57±0.08 nM(平均值±标准误)和188,000±18,000个位点/细胞;125I标记的tcu-PA为0.54±0.10 nM和132,000±23,900个位点/细胞;125I标记的DFP-tcu-PA分别为0.89±0.14 nM和143,000±30,300个位点/细胞。原代和传代培养(六代)的HUVECs的Kd值相似,但传代培养的HUVECs的Bmax值较低。在培养的猪内皮细胞中也发现了相似的Kd值;然而,Bmax值因内皮细胞类型而异。所有125I标记的尿激酶形式与培养的HUVECs产生相似的交联的约110-kDa配体-受体复合物,并且125I标记的DFP-tcu-PA在全细胞裂解物中与一种单一的主要约55-kDa蛋白结合(配体印迹/放射自显影),这表明在培养的HUVECs中存在一种单一的主要约55-kDa尿激酶受体。通过配体亲和色谱从几批不同的培养HUVECs(3-5微克蛋白质,约1×10^9个细胞)中分离出的约55-kDa尿激酶受体具有以下特性:通过配体印迹/放射自显影结合125I标记的rscu-PA以及形成交联的125I标记的约110-kDa rscu-PA-受体复合物证明其保留了生物活性;还原后为单链约55-kDa蛋白;用N-糖苷酶处理后完全转化并形成单一的主要去糖基化约35-kDa蛋白。